首页> 外文期刊>International journal of clinical rheumatology. >Current recommendations in the use of biologies for the treatment of rheumatic diseases in pregnant patients
【24h】

Current recommendations in the use of biologies for the treatment of rheumatic diseases in pregnant patients

机译:使用生物制剂治疗孕妇风湿病的最新建议

获取原文
获取原文并翻译 | 示例
           

摘要

Biological drugs have revolutionized the treatment of autoimmune rheumatic diseases and are used for an ever increasing proportion of patients. TNF inhibitors were the first to be introduced for the treatment of rheumatoid arthritis (RA), and have subsequently also shown efficacy in other autoimmune diseases. When treatment improves functional capacity and quality of life, patients of both genders wish to live normal lives including procreation. An increasing number of monoclonal antibodies wait for approval by governmental authorities. Many of these drugs will finally be used by female and male patients of fertile age who need to know whether these agents have adverse effects on fertility and reproduction. Since ethical considerations prevent studies of biological agents in pregnant women, knowledge on their effect on the developing fetus, and the newborn are gained only from inadvertent drug exposure. Manufacturers usually discourage use of biological agents in pregnant women because of lack of human data and out of fear of litigation.
机译:生物药物彻底改变了自身免疫性风湿性疾病的治疗方法,并用于越来越多的患者。 TNF抑制剂是第一种被引入治疗类风湿关节炎(RA)的抑制剂,后来也显示出在其他自身免疫性疾病中的功效。当治疗改善功能能力和生活质量时,男女患者都希望过正常的生活,包括生殖。越来越多的单克隆抗体等待政府当局的批准。这些药物中的许多最终将由育龄女性和男性患者使用,他们需要知道这些药物是否对生育和生殖产生不利影响。由于道德上的考虑阻止了孕妇对生物制剂的研究,因此仅通过无意间的药物接触即可获得有关其对发育中的胎儿和新生儿影响的知识。由于缺乏人类数据并且出于对诉讼的恐惧,制造商通常不鼓励孕妇使用生物制剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号